Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alzheimer's Disease (AD): early-phase trial registry
3 of 4 indexed Alzheimer's Disease (AD) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Alzheimer's Disease (AD): 4 US clinical trials tracked, 3 recruiting.
Alzheimer's Disease (AD) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Voyager Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition alzheimer39s-disease-ad
OPEN 3 | RECR 75% | LATE 0 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Alzheimer's Disease (AD) lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alzheimer's Disease (AD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alzheimer's Disease (AD) is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia
Fred Hutchinson Cancer Center
NCT06922188
Improving Executive Control in Cognitively Healthy Older Adults: the MUltitasking STrategy (MUST) Study
Rutgers, The State University of New Jersey
NCT06995638
Effects of Transcranial Ultrasound Stimulation (TUS) on Neurological and Cognitive Outcomes in Neurodegenerative Diseases
Sanmai Technologies PBC dba Sanmai
NCT07207122
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
Voyager Therapeutics
NCT06874621
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Alzheimer's Disease (AD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alzheimer's Disease (AD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alzheimer's Disease (AD) page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Alzheimer's Disease (AD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Voyager Therapeutics sponsors the most Alzheimer's Disease (AD) trials on record, review their full trial history before evaluating a specific study. See Voyager Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alzheimer's Disease (AD) condition card totals 4 registered trials; most-linked intervention VY7523; top US site state New Jersey. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.